Dr. Robert F. Vizza Lustgarten Clinical Accelerator Initiative (CAI)

The CAI reduces the time from clinical trial concept to launch using a Lustgarten-developed process based on the best available science and employing innovative biomarkers. These “smarter” clinical trials generate large volumes of data scientists use to help inform and improve current and future clinical trials and expedite new treatments.  

CAI studies are typically small, enrolling 10-20 patients, enabling the researchers to deeply analyze each patient and extract the most information possible. 

Clinical Accelerator Initiative trials include:


The TAG drives the success of the CAI by identifying, soliciting, vetting, and developing new clinical trial concepts based on the best available science.

Members represent the following institutions:

Dana-Farber Cancer Institute
Duke University
Johns Hopkins
Massachusetts General Hospital
MD Anderson
Memorial Sloan Kettering Cancer Center
Northwell Health
NYU Langone
Oregon Health & Science University
Princess Margaret Cancer Centre
UC San Diego
University of Pennsylvania

Thanks for signing up!
Tell us a little more about yourself: